Cargando…
Macrophage activation syndrome: early diagnosis is key
Macrophage activation syndrome (MAS) is a life-threatening condition, and it is a subset of hemophagocytic lymphohistiocytosis (HLH). The clinical features include a persistent high-grade fever, hepatosplenomegaly, lymphadenopathy, hemorrhagic manifestations, and a sepsis-like condition. From the cl...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124446/ https://www.ncbi.nlm.nih.gov/pubmed/30214327 http://dx.doi.org/10.2147/OARRR.S151013 |
_version_ | 1783353028397498368 |
---|---|
author | Lerkvaleekul, Butsabong Vilaiyuk, Soamarat |
author_facet | Lerkvaleekul, Butsabong Vilaiyuk, Soamarat |
author_sort | Lerkvaleekul, Butsabong |
collection | PubMed |
description | Macrophage activation syndrome (MAS) is a life-threatening condition, and it is a subset of hemophagocytic lymphohistiocytosis (HLH). The clinical features include a persistent high-grade fever, hepatosplenomegaly, lymphadenopathy, hemorrhagic manifestations, and a sepsis-like condition. From the clinical features, it is usually difficult to differentiate between a true sepsis, disease flare-ups, or MAS. Although the laboratory abnormalities are similar to those of a disseminated intravascular coagulation, which shows pancytopenia, coagulopathy, hypofibrinogenemia, and an elevated d-dimer test, it can also be a late stage of MAS. Currently, MAS is still underrecognized and usually results in delayed in diagnosis, which leads to high morbidity and mortality. This literature review was conducted in the context of the clinical manifestations and the laboratory abnormalities in MAS, which might provide some clues for an early diagnosis. The best ways for an early recognition and a satisfactory diagnosis were based on the relative changes in the overall parameters from the baseline, together with a thorough and continuous physical examination for these kinds of patients. At present, diagnostic criteria have been proposed for HLH, MAS-associated systemic juvenile idiopathic arthritis, and an MAS-associated systemic lupus erythematosus. Therefore, selecting the proper diagnostic criteria for use is essential because not all of the criteria are suitable for every autoimmune disease. |
format | Online Article Text |
id | pubmed-6124446 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-61244462018-09-13 Macrophage activation syndrome: early diagnosis is key Lerkvaleekul, Butsabong Vilaiyuk, Soamarat Open Access Rheumatol Review Macrophage activation syndrome (MAS) is a life-threatening condition, and it is a subset of hemophagocytic lymphohistiocytosis (HLH). The clinical features include a persistent high-grade fever, hepatosplenomegaly, lymphadenopathy, hemorrhagic manifestations, and a sepsis-like condition. From the clinical features, it is usually difficult to differentiate between a true sepsis, disease flare-ups, or MAS. Although the laboratory abnormalities are similar to those of a disseminated intravascular coagulation, which shows pancytopenia, coagulopathy, hypofibrinogenemia, and an elevated d-dimer test, it can also be a late stage of MAS. Currently, MAS is still underrecognized and usually results in delayed in diagnosis, which leads to high morbidity and mortality. This literature review was conducted in the context of the clinical manifestations and the laboratory abnormalities in MAS, which might provide some clues for an early diagnosis. The best ways for an early recognition and a satisfactory diagnosis were based on the relative changes in the overall parameters from the baseline, together with a thorough and continuous physical examination for these kinds of patients. At present, diagnostic criteria have been proposed for HLH, MAS-associated systemic juvenile idiopathic arthritis, and an MAS-associated systemic lupus erythematosus. Therefore, selecting the proper diagnostic criteria for use is essential because not all of the criteria are suitable for every autoimmune disease. Dove Medical Press 2018-08-31 /pmc/articles/PMC6124446/ /pubmed/30214327 http://dx.doi.org/10.2147/OARRR.S151013 Text en © 2018 Lerkvaleekul and Vilaiyuk. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Lerkvaleekul, Butsabong Vilaiyuk, Soamarat Macrophage activation syndrome: early diagnosis is key |
title | Macrophage activation syndrome: early diagnosis is key |
title_full | Macrophage activation syndrome: early diagnosis is key |
title_fullStr | Macrophage activation syndrome: early diagnosis is key |
title_full_unstemmed | Macrophage activation syndrome: early diagnosis is key |
title_short | Macrophage activation syndrome: early diagnosis is key |
title_sort | macrophage activation syndrome: early diagnosis is key |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124446/ https://www.ncbi.nlm.nih.gov/pubmed/30214327 http://dx.doi.org/10.2147/OARRR.S151013 |
work_keys_str_mv | AT lerkvaleekulbutsabong macrophageactivationsyndromeearlydiagnosisiskey AT vilaiyuksoamarat macrophageactivationsyndromeearlydiagnosisiskey |